NL-OMON29021Other不适用
Therapeutic drug monitoring of TNF-alpha blockers in IBD, a prospective single center cohort experience compared to biologicals in the pre-TDM era
oordwest Ziekenhuisgroep0 个研究点目标入组 275 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- Other
- 发起方
- 入组人数
- 275
研究概览
简要总结
Intentions are publication in an international peer reviewed scientific magazine.
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •For the historical cohort:
- •- All patients who were 18 years and older on 01-01-2016 and no longer being cared for by our paediatricians
排除标准
- •-Any IBD-patient (who was) participating in a clinical trial for one of these biologicals that dictated/s an alternative treatment regimen than was/is used in clinical practice.
- •- Any IBD patient whose treatment indication for infliximab or adalimumab is/was not primarily for IBD during the study periods (such as rheumatoid arthritis or psoriasis).
研究者
相似试验
已完成
不适用
Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel DiseaseUlcerative ColitisCrohn's DiseaseInflammatory Bowel DiseaseNCT02073526Oslo University Hospital1,230
已完成
不适用
Therapeutic Drug Monitoring of New Generation Antiepileptic DrugsEpilepsyNCT02739282Dr Jan Novy151
已完成
不适用
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)Inflammatory Bowel DiseasesNCT01971970Erasmus Medical Center45
已完成
不适用
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative ColitisNCT02508012University Hospital, Montpellier260
招募中
不适用
Therapeutic Monitoring of Infliximab and AdalimumabInflammatory Bowel DiseasesNCT06033469IRCCS Burlo Garofolo100